175 related articles for article (PubMed ID: 30619250)
21. CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors.
Sapsutthipas S; Tsuchiya N; Pathipavanich P; Ariyoshi K; Sawanpanyalert P; Takeda N; Isarangkura-na-ayuthaya P; Kameoka M
PLoS One; 2013; 8(1):e53920. PubMed ID: 23308290
[TBL] [Abstract][Full Text] [Related]
22. Glycan-Dependent Neutralizing Antibodies Are Frequently Elicited in Individuals Chronically Infected with HIV-1 Clade B or C.
Cohen YZ; Lavine CL; Miller CA; Garrity J; Carey BR; Seaman MS
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1192-201. PubMed ID: 26149894
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
van Gils MJ; Edo-Matas D; Schweighardt B; Wrin T; Schuitemaker H
J Gen Virol; 2010 Jan; 91(Pt 1):250-8. PubMed ID: 19793903
[TBL] [Abstract][Full Text] [Related]
24. Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years.
Cao W; Wang X; Li B; Lin L; Du Z; Zhao H; Zhang Y; Xu Z; Qiao Y
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307159
[TBL] [Abstract][Full Text] [Related]
25. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
[TBL] [Abstract][Full Text] [Related]
26. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies.
Serwanga J; Ssemwanga D; Muganga M; Nakiboneka R; Nakubulwa S; Kiwuwa-Muyingo S; Morris L; Redd AD; Quinn TC; Kaleebu P;
Vaccine; 2018 Jan; 36(4):578-586. PubMed ID: 29274699
[TBL] [Abstract][Full Text] [Related]
28. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
29. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
30. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
Gray ES; Madiga MC; Hermanus T; Moore PL; Wibmer CK; Tumba NL; Werner L; Mlisana K; Sibeko S; Williamson C; Abdool Karim SS; Morris L;
J Virol; 2011 May; 85(10):4828-40. PubMed ID: 21389135
[TBL] [Abstract][Full Text] [Related]
31. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
[TBL] [Abstract][Full Text] [Related]
32. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.
Hraber P; Seaman MS; Bailer RT; Mascola JR; Montefiori DC; Korber BT
AIDS; 2014 Jan; 28(2):163-9. PubMed ID: 24361678
[TBL] [Abstract][Full Text] [Related]
33. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
[TBL] [Abstract][Full Text] [Related]
34. Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.
Khan L; Makhdoomi MA; Kumar S; Nair A; Andrabi R; Clark BE; Auyeung K; Bhattacharya J; Vajpayee M; Wig N; Pantophlet R; Luthra K
PLoS One; 2015; 10(5):e0125575. PubMed ID: 25962059
[TBL] [Abstract][Full Text] [Related]
35. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
[TBL] [Abstract][Full Text] [Related]
36. Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers.
Ren C; Liu S; Li Y; Zhuang M; Yu H; Wang J; Sun F; Li D; Zhang H; Liu W; Liang S; Zhong P; Ling H
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):472-80. PubMed ID: 25202919
[TBL] [Abstract][Full Text] [Related]
37. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
38. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
[TBL] [Abstract][Full Text] [Related]
39. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.
Ozkaya Sahin G; Holmgren B; da Silva Z; Nielsen J; Nowroozalizadeh S; Esbjörnsson J; Månsson F; Andersson S; Norrgren H; Aaby P; Jansson M; Fenyö EM
J Virol; 2012 Jan; 86(2):961-71. PubMed ID: 22072782
[TBL] [Abstract][Full Text] [Related]
40. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
